Tumor progression: the effects of thrombospondin-1 and -2
- 17 March 2004
- journal article
- review article
- Published by Elsevier in The International Journal of Biochemistry & Cell Biology
- Vol. 36 (6), 1038-1045
- https://doi.org/10.1016/j.biocel.2004.01.008
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapyProceedings of the National Academy of Sciences, 2003
- Low Dose Carboplatin Combined With Angiostatic Agents Prevents Metastasis in Human Testicular Germ Cell Tumor XenograftsJournal of Urology, 2003
- Thrombospondins 1 and 2 function as inhibitors of angiogenesisMatrix Biology, 2003
- Thrombospondin 1--a regulator of adenoma growth and carcinoma progression in the APCMin/+ mouse modelCarcinogenesis: Integrative Cancer Research, 2003
- Thrombospondins and tumor angiogenesisTrends in Molecular Medicine, 2001
- In vivo mechanisms by which tumors producing thrombospondin 1 bypass its inhibitory effectsGenes & Development, 2001
- The role of VEGF and thrombospondins in skin angiogenesisJournal of Dermatological Science, 2000
- Thrombospondin Type 1 Repeats Interact with Matrix Metalloproteinase 2Journal of Biological Chemistry, 2000
- The Wilms' tumor gene product represses the transcription of thrombospondin 1 in response to overexpression of c-JunOncogene, 1999
- Three Distinct d-Amino Acid Substitutions Confer Potent Antiangiogenic Activity on an Inactive Peptide Derived from a Thrombospondin-1 Type 1 RepeatMolecular Pharmacology, 1999